CN108949613B - Antibiotic-assisting probiotic preparation and preparation method thereof - Google Patents
Antibiotic-assisting probiotic preparation and preparation method thereof Download PDFInfo
- Publication number
- CN108949613B CN108949613B CN201810607252.9A CN201810607252A CN108949613B CN 108949613 B CN108949613 B CN 108949613B CN 201810607252 A CN201810607252 A CN 201810607252A CN 108949613 B CN108949613 B CN 108949613B
- Authority
- CN
- China
- Prior art keywords
- enterococcus faecium
- preparation
- probiotic preparation
- probiotic
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 70
- 239000006041 probiotic Substances 0.000 title claims abstract description 57
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 57
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 57
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 42
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 17
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 17
- 238000004321 preservation Methods 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims description 34
- 230000004151 fermentation Effects 0.000 claims description 34
- 229920002472 Starch Polymers 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 235000019698 starch Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 229940041514 candida albicans extract Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012138 yeast extract Substances 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 9
- 229910001868 water Inorganic materials 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 238000011218 seed culture Methods 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005273 aeration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 15
- 241000894006 Bacteria Species 0.000 abstract description 10
- 241000700605 Viruses Species 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 38
- 241000588724 Escherichia coli Species 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 20
- 241000701931 Canine parvovirus Species 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 8
- 244000063299 Bacillus subtilis Species 0.000 description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 description 7
- 241000125945 Protoparvovirus Species 0.000 description 6
- 241000607142 Salmonella Species 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 208000028774 intestinal disease Diseases 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 241001106597 Enterococcus lactis Species 0.000 description 2
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960004817 etamsylate Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
The invention discloses a probiotic preparation for assisting antibiotics and a preparation method thereof, belonging to the field of animal health products. The probiotic preparation comprises enterococcus faecium, wherein the enterococcus faecium is preserved in China center for type culture collection (CCTCC NO: M2017733) in 2017, 11 months and 27 days, and the preservation address is university of China, Wuhan and Wuhan. The embodiment of the invention provides a probiotic preparation for assisting antibiotics, which can be used for assisting in treating various intestinal diarrhea diseases of pets caused by viruses and bacteria and has a good treatment effect on intractable diarrhea accompanied by late recovery of the diseases of the pets.
Description
Technical Field
The invention relates to the field of animal health products, in particular to a probiotic preparation for assisting antibiotics and a preparation method thereof.
Background
In recent years, with the increasing improvement of the living standard of people in China and the acceleration of work rhythm, the pet feeding becomes a life mode for relieving work pressure and promoting physical and mental health, and pet owners pay more and more attention to the life quality of pets. Pets live in indoor environment for a long time and the immunity of the pets is easy to be reduced only by eating the formula pet daily ration, so that the pets can be infected by virus or bacteria.
The most common treatment method for viral infection of pets comprises the use of antibiotics, and the wide use of antibiotics in viral infection of pets can cause drug resistance of pathogenic bacteria in pet intestines and destroy beneficial bacteria in the intestines, so that the pets can cause intestinal diseases, including vomiting or diarrhea, and the pets often die of the intestinal diseases caused by viral infection after the viral or bacterial infection is cured. At present, a probiotic preparation product can be used for assisting antibiotics to treat viral infection of pets, the probiotic preparation product is an active microorganism which plays a role by improving the balance of host intestinal microbial flora, and the active microorganism can improve the balance of host intestinal microorganisms after being orally taken, so that the aim of assisting in treating intestinal diseases of pets is fulfilled, and beneficial influence is generated on the health of hosts.
In the process of implementing the invention, the inventor finds that the prior art has at least the following problems:
the existing probiotic preparation product has low cure rate for the adjuvant therapy of intestinal diseases of pets caused by virus infection and bacterial infection.
Disclosure of Invention
In order to solve the problem that the cure rate of the probiotic preparation product in the prior art is low in treatment of intestinal diseases of pets caused by virus infection and bacterial infection, the embodiment of the invention provides a probiotic preparation for assisting antibiotics and a preparation method thereof. The technical scheme is as follows:
the embodiment of the invention provides a probiotic preparation for assisting antibiotics, which comprises enterococcus faecium, wherein the enterococcus faecium is preserved in China center for type culture collection (CCTCC NO: M2017733) in 2017, 11 months and 27 days, and the preservation address is China, Wuhan and Wuhan university, and the preservation number is CCTCC NO: M2017733.
Specifically, the probiotic preparation further comprises a carrier, the mass ratio of the carrier to the enterococcus faecium is 2 (3-4), and the carrier comprises: the starch-containing composite material comprises soluble starch and maltodextrin, wherein the mass ratio of the soluble starch to the maltodextrin is (7-8) to (2-3).
In another aspect, the embodiment of the present invention provides a preparation method of a probiotic preparation, where the preparation method includes:
inoculating the original strain of enterococcus faecium into a seed culture medium, and carrying out shake culture on the mixed solution at 35-37 ℃ to obtain a seed solution of enterococcus faecium;
and inoculating the seed solution into a precipitate-free fermentation culture medium to obtain a mixed solution, and performing fermentation culture at 35-37 ℃ to obtain the enterococcus faecium, namely the probiotic preparation.
Specifically, the rotation speed of the shaking culture is 150-200 r/min, and the time of the shaking culture is 20-24 h.
Specifically, the seed culture medium comprises: yeast extract, peptone, beef extract, glucose, diammonium hydrogen citrate, sodium acetate, magnesium sulfate heptahydrate and water.
Specifically, the precipitate-free fermentation medium comprises: the bean cake comprises bean cake soaking powder, yeast extract, starch, glucose, potassium dihydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate and water, wherein the mass ratio of the bean cake soaking powder to the yeast extract to the starch to the glucose to the potassium dihydrogen phosphate to the disodium hydrogen phosphate to the magnesium sulfate to the water is (8-10): 5-10): 2-4): 5-8): 0.05-0.1): 0.1-0.2): 1000.
Specifically, during the fermentation culture, the mixed solution is stirred, and the stirring speed is 200-240 r/min.
Specifically, a fermentation tank is adopted for the fermentation culture, and the ventilation volume in the fermentation tank is 0.5-1 m2The fermentation time is 20-24 h.
Specifically, the preparation method further comprises the following steps: mixing the enterococcus faecium and the carrier, and then granulating and drying.
Further, a fluidized bed dryer is adopted for drying, the air inlet temperature is 85-120 ℃, the air outlet temperature is 50-60 ℃, and the drying time is 15 min.
The embodiment of the invention provides a probiotic preparation for assisting antibiotics, which comprises enterococcus faecium, wherein the enterococcus faecium belongs to the enterococcus lactis, and is adhered to gastrointestinal mucosa after entering an animal intestinal tract by oral administration, so that pathogenic bacteria such as escherichia coli, salmonella and the like are blocked from being fixedly planted in the gastrointestinal tract, and the pathogenic bacteria such as the escherichia coli, the salmonella and the like are discharged along with excrement; enterococcus faecium is facultative anaerobe, enters gastrointestinal tracts to propagate and consume oxygen in the gastrointestinal tracts, pathogenic bacteria such as escherichia coli and salmonella are aerobic bacteria, and the growth of the pathogenic bacteria is inhibited by the consumption of the oxygen. The probiotic preparation provided by the embodiment of the invention has a high cure rate in treating colibacillosis diarrhea of dogs. The probiotic preparation enters the gastrointestinal tract of pets by oral administration, competes with viruses for gastrointestinal mucosal cell receptors, and blocks the combination of the viruses and the gastrointestinal tract cells and the invasion of the viruses into the cells; meanwhile, the probiotic preparation can neutralize parvovirus. The probiotic preparation provided by the embodiment of the invention has a high cure rate in treating canine parvovirus disease diarrhea. The enterococcus faecium in the probiotic preparation can be propagated in gastrointestinal tract, inhibit growth and propagation of pathogenic bacteria such as Escherichia coli, prevent pet diseases, promote growth of beneficial bacteria such as lactobacillus, stimulate animals to generate immune response, and enhance disease resistance of animals. The probiotic preparation can be used for adjuvant treatment of various intestinal diarrhea diseases of pets caused by viruses and bacteria, and has good treatment effect on intractable diarrhea accompanied by late rehabilitation of pet diseases.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
FIG. 1 is a graph of defecation after 10 days of group A treatment provided by an embodiment of the present invention;
FIG. 2 is a graph of defecation after 10 days of group B treatment as provided by an embodiment of the invention.
Detailed Description
The following embodiments are described in detail with reference to the accompanying drawings, so that how to implement the technical features of the present invention to solve the technical problems and achieve the technical effects can be fully understood and implemented.
The embodiment of the invention provides a probiotic preparation for assisting antibiotics, wherein the probiotic preparation comprises enterococcus faecium. The Enterococcus faecium Latin is named as Enterococcus faecium M31, and is preserved in China Center for Type Culture Collection (CCTCC) in 2017, 11.27.7.M, with the preservation address of university in China, Wuhan and Wuhan, and the preservation number of M2017733.
The embodiment of the invention also provides a preparation method of the probiotic preparation for assisting antibiotics, which comprises the following steps:
specifically, the probiotic preparation further comprises a carrier, the mass ratio of the carrier to the enterococcus faecium is 2 (3-4), and the carrier comprises: the starch-based composite material comprises soluble starch and maltodextrin, wherein the mass ratio of the soluble starch to the maltodextrin is (7-8) to (2-3).
In another aspect, an embodiment of the present invention provides a method for preparing a probiotic preparation, where the method includes:
inoculating an original strain of enterococcus faecium into a seed culture medium, and performing shaking culture at 35-37 ℃ to obtain a seed solution of enterococcus faecium;
and inoculating the seed liquid into a precipitate-free fermentation culture medium to obtain a mixed liquid, and performing fermentation culture at the temperature of 35-37 ℃ to obtain enterococcus faecium, namely the probiotic preparation.
Specifically, the rotation speed of the shaking culture is 150-200 r/min, and the time of the shaking culture is 20-24 h.
Specifically, the seed culture medium comprises: yeast extract, peptone, beef extract, glucose, diammonium hydrogen citrate, sodium acetate, magnesium sulfate heptahydrate and water.
Specifically, the precipitate-free fermentation medium comprises: the weight ratio of the bean cake soaking powder to the yeast extract to the starch to the glucose to the potassium dihydrogen phosphate to the disodium hydrogen phosphate to the magnesium sulfate to the water is (8-10): 5-10): 2-4): 5-8): 0.05-0.1 ]: 0.1-0.2): 1000.
Specifically, during fermentation culture, the mixed solution is stirred at the rotation speed of 200-240 r/min.
Specifically, a fermentation tank is adopted for fermentation culture, and the ventilation volume in the fermentation tank is 0.5-1 m2The fermentation time is 20-24 h.
Specifically, the preparation method further comprises the following steps: the enterococcus faecium is mixed with the carrier, and then granulation and drying are carried out.
Further, drying by a fluidized bed dryer, wherein the air inlet temperature is 85-120 ℃, the air outlet temperature is 50-60 ℃ and drying is carried out for 15 min.
Examples
The embodiment of the invention provides a probiotic preparation for assisting antibiotics, which comprises the following components: enterococcus faecium and a carrier, wherein the carrier comprises: the mass ratio of the carrier to the enterococcus faecium is 2:3, and the mass ratio of the soluble starch to the maltodextrin is 7: 3. In addition, the probiotic formulation may further comprise: the mass ratio of the enterococcus faecium to the flavoring agent to the sweetening agent is 1:0.005: 0.001.
In implementation, the sweetener can be sweetener N90, available from Chengdu Dadi Hank Biotech Co., Ltd; the flavoring agent can be porket flavor, and is available from Shanghai Meinong Biotech limited.
The following describes a method for preparing a probiotic preparation, which comprises:
preparing a seed culture medium: respectively weighing 5 parts of yeast extract, 10 parts of peptone, 10 parts of beef extract, 20 parts of glucose, 2 parts of diammonium hydrogen citrate, 5 parts of sodium acetate, 0.58 part of magnesium sulfate heptahydrate and 1000 parts of distilled water according to the parts by weight, uniformly mixing, adding into a seeding tank, heating the seeding tank to 90-100 ℃ to kill infectious microbes, keeping the temperature for 1h to kill the infectious microbes, sterilizing, and cooling to 30 +/-5 ℃ to obtain the seed culture medium.
Inoculating an original strain of enterococcus faecium into a seed culture medium according to an inoculation amount with a volume ratio of 1:100, and performing shaking culture at 35-37 ℃ for 20-24 h at a rotation speed of 150-00 r/min to obtain a seed solution of enterococcus faecium.
Preparing a precipitate-free fermentation medium, wherein the precipitate-free fermentation medium comprises: the soybean cake comprises cake soaking powder, yeast extract, starch, glucose, potassium dihydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate and water, wherein the mass ratio of the soybean cake soaking powder to the yeast extract to the starch to the glucose to the potassium dihydrogen phosphate to the disodium hydrogen phosphate to the magnesium sulfate to the water is (8-10): 5-10): 2-4): 5-8): 0.05-0.1): 0.1-0.2): 1000.
Weighing the raw materials of the precipitate-free fermentation medium according to the mass ratio, adding the raw materials into a fermentation tank, heating the fermentation tank to 90-100 ℃ to kill the mixed bacteria, keeping the temperature for 1h, sterilizing, and cooling to 30 +/-5 ℃ to obtain the precipitate-free fermentation medium.
Inoculating the seed liquid of enterococcus faecium into a precipitate-free fermentation medium according to the volume ratio of 1:100, wherein the fermentation temperature is 35-37 ℃, the fermentation speed is 200-240 r/min, and the fermentation ventilation volume is 0.5-1 m2And h, fermenting for 20-24 h to obtain the enterococcus faecium fermentation liquid, wherein the viable count of the enterococcus faecium in the enterococcus faecium fermentation liquid is more than or equal to 30 hundred million.
The enterococcus faecium is mixed with the carrier, and then granulation and drying are carried out.
Specifically, a fluidized bed dryer is adopted for drying, the air inlet temperature is 85-120 ℃, the air outlet temperature is 50-60 ℃, and the drying time is 15 min.
Application test of probiotic preparation provided by the embodiment of the invention in adjuvant therapy of canine parvovirus disease by antibiotics
Selecting the sick dogs with symptoms of emaciation, anorexia, vomiting, diarrhea and the like, detecting canthus secretions, nasal secretion, serum and rectal contents of the sick dogs by using the canine parvovirus antigen detection cards, selecting 10 sick dogs with positive detection of the canine parvovirus antigen detection cards, averagely dividing the sick dogs into A, B groups, and treating the sick dogs according to the following method:
group A: 10mL/kg of physiological saline, 8 ten thousand IU of gentamicin, 30mL/kg of glucose with the concentration of 5 percent, 20mg/kg of ribavirin injection and 1.0mL/kg of canine parvovirus monoclonal antibody, 0.2mL/kg of etamsylate and 0.3mL/kg of bromfenaprocaine injection are injected subcutaneously for continuous treatment for 5 days; at the later stage, 4-10g/d of Bacillus subtilis preparation is used, and the preparation is orally taken for 5 days; the bacillus subtilis preparation is purchased from Hubei Huada Dare science and technology Limited company, and has the specification: the number of viable bacillus subtilis is 200 hundred million/g, and the batch number is as follows: 2017122001.
group B: 10mL/kg of physiological saline, 8 ten thousand IU of gentamicin, 30mL/kg of glucose with the concentration of 5 percent, 20mg/kg of ribavirin injection and 1.0mL/kg of canine parvovirus monoclonal antibody, 0.2mL/kg of etamsylate and 0.3mL/kg of bromfenaprocaine injection are injected subcutaneously for continuous treatment for 5 days; the probiotic preparation provided by the embodiment of the invention is used at the later stage in 4-10g/d, and is orally taken for 2 times and continuously for 5 days.
The treatment results are as follows: in group A, after 10 days of continuous treatment, the body temperature of 5 cases of dogs recovered to normal, and parvovirus was not detected in the ocular secretion and blood, but anorexia and loose stool were observed in the whole of 3 cases of dogs, and one of the stool of the dog was shown in FIG. 1.
In group B, after 10 days of continuous treatment, the body temperature of the sick dogs recovered to normal, parvovirus was not detected in the canthus secretions and blood, the daily average feed intake was 1 time that of group A, and 4 cases of normal defecation were normal except 1 case of loose stool, and the feces of one of the dogs were normal as shown in FIG. 2.
Therefore, the cure rate of intestinal diarrhea of the group B using the probiotic preparation provided by the embodiment of the invention is 80%, and the cure rate of diarrhea of the group A is 40% when the auxiliary antibiotic is used for treating parvovirus. The enterococcus faecium M31 in the probiotic preparation provided by the embodiment of the invention enters the gastrointestinal tract of pets through oral administration, and can compete with canine parvovirus diseases for gastrointestinal mucosal cell receptors, block the combination of the canine parvovirus diseases and gastrointestinal tract cells and the invasion of the canine parvovirus diseases and the gastrointestinal tract cells, reduce diarrhea caused by the parvovirus and improve the cure rate of the diarrhea.
The probiotic preparation provided by the embodiment of the invention is applied to an auxiliary antibiotic treatment of canine Escherichia coli (bacteria).
Selected from 6 months to 12 months in 2017, diarrhea-affected dogs in college of agriculture in Wuhan Huazhong veterinary hospital and Wuhan certain pet hospital, and canine distemper and canine parvovirus antigen detection cards are used for removing the affected dogs with the viral diarrhea. 24 sick dogs suffering from diarrhea caused by Escherichia coli are selected by using a separation culture method, a physiological biochemical identification method and a serological identification method, and are averagely and randomly divided into A, B two groups, 12 cases in the A group and 12 cases in the B group. Two groups of sick dogs are respectively treated by the following methods:
group A: 8 ten thousand IU of gentamicin, 10mg/kg of amoxicillin and 4 hours after the administration of antibiotics, feeding a bacillus subtilis preparation, and orally taking for 2-3 times/day, wherein 7 days is a treatment course; the bacillus subtilis preparation is purchased from Hubei Huada Dare science and technology Limited company, and has the specification: the number of viable bacillus subtilis is 238 hundred million/g, and the batch number is as follows: 2018010802.
group B: 8 ten thousand IU of gentamicin and 10mg/kg of amoxicillin, and 4 hours after the antibiotics are administered, the probiotic preparation provided by the embodiment of the invention is fed in drinking water, the oral administration is carried out for 2-3 times per day, 1g of the probiotic preparation is fed per kilogram of body weight of the sick dog every time, and 7 days is a treatment course.
And judging the treatment effect by adopting the condition of the eye diarrhea and the separation and identification of the Escherichia coli in the excrement. Observing the condition of the diarrhea under the eye, observing the defecation condition of each group of sick dogs after each treatment course, judging that no treatment is given when defecation sample, bloody stool or loose stool appears, and judging that the treatment is given when the treatment is given otherwise. The fecal Escherichia coli number of the healthy dog is maintained at 1-3 multiplied by 107cfu/g, when the number of Escherichia coli in feces is detected to be larger than a normal value, the Escherichia coli is judged to be not cured, and otherwise, the Escherichia coli is judged to be cured. When the eye observation result is consistent with the Escherichia coli separation and identification result, the cure can be judged. In the sick dogs in the group A, after 7 days, namely the first treatment course, the sick symptoms of 5 sick dogs are eliminated, and the cure rate is 41.6 percent; after the second course of treatment, the symptoms of the disease were eliminated in 9 dogs and there were still 3 dogs with anorexia and mild diarrhea. In the sick dogs in group B, after 7 days of administration, the disease symptoms of 8 sick dogs are eliminated, after 14 days of administration, the disease symptoms of 12 sick dogs are eliminated, and the normal quantity of Escherichia coli in excrement is detected, so that the probiotic preparation can kill Escherichia coli and reduce the occurrence of diarrhea.
Table 1 shows the healing conditions
As can be seen from Table 1, the probiotic formulation of group B was superior to the Bacillus subtilis formulation of group A in the adjuvant antibiotic treatment of Escherichia coli disease in dogs after 14 days of use, i.e., after 2 courses of treatment.
Table 2 shows the results of the study of the bacterial population of treated dogs
In Table 2, log10 represents the viable cell count, and the same letters on the same row indicate insignificant difference (p >0.05), and the same letters on the same row indicate significant difference (p < 0.05).
As can be seen from table 2, when the probiotic preparation provided by the embodiment of the present invention is used, the number of escherichia coli in the canine intestinal tract is in a downward trend, and the number of escherichia coli in group B is significantly less than that in group a; this shows that the probiotic preparation provided by the embodiment of the invention has a better effect in inhibiting escherichia coli. The test results also show that the beneficial bacteria lactobacillus in the B group is more than the beneficial bacteria lactobacillus in the A group. The probiotic preparation in the group B enters the gastrointestinal tract of the dog by oral administration of the dog, consumes oxygen in the gastrointestinal tract for growth and reproduction, and promotes the growth of beneficial bacteria such as lactobacillus.
Application test of probiotic preparation provided by the embodiment of the invention in healthy pet dogs
12 healthy golden hair pet dogs with similar weight at 120 days of age are selected in a pet dog breeding factory in Wuhan City and randomly divided into A, B groups, each group comprises 6 dogs, the A group is fed with basic dog food, the B group is fed with basic dog food and probiotic preparation, and the dosage of the probiotic preparation is 4 g/d. The feeding period is from 2017, 9, month 1 and 9, month 30, and the total period is 30 days. Specific results are shown in table 3.
Table 3 shows daily average food consumption and diarrhea rate statistics
As can be seen from Table 3, the daily average feed intake of group B was increased by 4.7%, the diarrhea rate was reduced by 27.8% compared to group A, and the dogs of group B were mentally active and well developed. Therefore, the probiotic preparation provided by the embodiment of the invention can effectively improve the appetite of healthy pet dogs, promote food intake, regulate the intestinal microecological balance and reduce the diarrhea rate, thereby being beneficial to the intestinal health of pets.
The embodiment of the invention provides a probiotic preparation for assisting antibiotics, which comprises enterococcus faecium, wherein the enterococcus faecium belongs to the enterococcus lactis, and is adhered to gastrointestinal mucosa after entering an animal intestinal tract by oral administration, so that pathogenic bacteria such as escherichia coli, salmonella and the like are blocked from being fixedly planted in the gastrointestinal tract, and the pathogenic bacteria such as the escherichia coli, the salmonella and the like are discharged along with excrement; enterococcus faecium is facultative anaerobe, enters gastrointestinal tracts to propagate and consume oxygen in the gastrointestinal tracts, pathogenic bacteria such as escherichia coli and salmonella are aerobic bacteria, and the growth of the pathogenic bacteria is inhibited by the consumption of the oxygen. The probiotic preparation provided by the embodiment of the invention has a high cure rate in treating colibacillosis diarrhea of dogs. The probiotic preparation enters the gastrointestinal tract of pets by oral administration, competes with viruses for gastrointestinal mucosal cell receptors, and blocks the combination of the viruses and the gastrointestinal tract cells and the invasion of the viruses into the cells; meanwhile, the probiotic preparation can neutralize parvovirus. The probiotic preparation provided by the embodiment of the invention has a high cure rate in treating canine parvovirus disease diarrhea. The enterococcus faecium in the probiotic preparation can be propagated in gastrointestinal tract, inhibit growth and propagation of pathogenic bacteria such as Escherichia coli, prevent pet diseases, promote growth of beneficial bacteria such as lactobacillus, stimulate animals to generate immune response, and enhance disease resistance of animals. The probiotic preparation can be used for adjuvant treatment of various intestinal diarrhea diseases of pets caused by viruses and bacteria, and has good treatment effect on intractable diarrhea accompanied by late rehabilitation of pet diseases.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. The probiotic preparation for assisting antibiotics is characterized by comprising enterococcus faecium which is preserved in China center for type culture collection (CCTCC NO: M2017733) in 2017, 11 months and 27 days, wherein the preservation address is China, Wuhan and Wuhan university, and the preservation number is CCTCC NO: M2017733.
2. The probiotic preparation according to claim 1, further comprising a carrier, wherein the mass ratio of the carrier to the enterococcus faecium is 2 (3-4), and the carrier comprises: the starch-containing composite material comprises soluble starch and maltodextrin, wherein the mass ratio of the soluble starch to the maltodextrin is (7-8) to (2-3).
3. A method of preparing a probiotic formulation according to any of claims 1 to 2, characterized in that it comprises:
inoculating the original strain of enterococcus faecium into a seed culture medium, and performing shaking culture at 35-37 ℃ to obtain a seed solution of enterococcus faecium;
and inoculating the seed liquid into a precipitate-free fermentation culture medium to obtain a mixed liquid, and performing fermentation culture on the mixed liquid at the temperature of 35-37 ℃ to obtain the enterococcus faecium.
4. The method according to claim 3, wherein the rotation speed of the shaking culture is 150 to 200r/min, and the time of the shaking culture is 20 to 24 hours.
5. The method of claim 3, wherein the seed medium comprises: yeast extract, peptone, beef extract, glucose, diammonium hydrogen citrate, sodium acetate, magnesium sulfate heptahydrate and water.
6. The method of claim 3, wherein the precipitate-free fermentation medium comprises: bean cake soaking powder, yeast extract, starch, glucose, potassium dihydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate and water.
7. The method according to claim 3, wherein the mixed solution is stirred during the fermentation culture at a rotation speed of 200 to 240 r/min.
8. The method according to claim 3, wherein the fermentation culture is carried out in a fermenter having an aeration rate of 0.5 to 1m2The fermentation time is 20-24 h.
9. The method of manufacturing according to claim 3, further comprising: mixing the enterococcus faecium and the carrier, and then granulating and drying.
10. The preparation method of claim 9, wherein the drying is performed by a fluidized bed dryer, and the air inlet temperature is 85-120 ℃, the air outlet temperature is 50-60 ℃, and the drying time is 15 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810607252.9A CN108949613B (en) | 2018-06-13 | 2018-06-13 | Antibiotic-assisting probiotic preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810607252.9A CN108949613B (en) | 2018-06-13 | 2018-06-13 | Antibiotic-assisting probiotic preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108949613A CN108949613A (en) | 2018-12-07 |
| CN108949613B true CN108949613B (en) | 2021-03-23 |
Family
ID=64488799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810607252.9A Active CN108949613B (en) | 2018-06-13 | 2018-06-13 | Antibiotic-assisting probiotic preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108949613B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114540239B (en) * | 2022-03-10 | 2023-03-14 | 浙江大学 | Rabbit-derived enterococcus faecium ZJUIDS-R1 for preventing pet diarrhea and application thereof |
| CN116836894B (en) * | 2023-09-01 | 2023-12-01 | 小宠爱(北京)科技有限公司 | Enterococcus faecium capable of improving carbohydrate decomposition capability and application thereof in regulating intestinal microecological environment of pets |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102747003A (en) * | 2011-12-29 | 2012-10-24 | 武汉华大瑞尔科技有限公司 | Screening and application of probiotic Enterococcus faecium |
| CN103764154A (en) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
| CN104862254A (en) * | 2015-05-26 | 2015-08-26 | 北京好实沃生物技术有限公司 | Enterococcus faecium HEW-A588 and application thereof |
-
2018
- 2018-06-13 CN CN201810607252.9A patent/CN108949613B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103764154A (en) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
| CN102747003A (en) * | 2011-12-29 | 2012-10-24 | 武汉华大瑞尔科技有限公司 | Screening and application of probiotic Enterococcus faecium |
| CN104862254A (en) * | 2015-05-26 | 2015-08-26 | 北京好实沃生物技术有限公司 | Enterococcus faecium HEW-A588 and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Supplementation of Food with Enterococcus faecium (SF68) Stimulates Immune Functions in Young Dogs;Jalil Benyacoub等;《The Journal of nutrition》;20030430;第133卷(第4期);1158-1162 * |
| 犬源益生菌的筛选及其对犬细菌性腹泻的治疗试验;任普军;《中国优秀硕士学位论文全文数据库 农业科技辑》;20080415(第04期);D050-181 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108949613A (en) | 2018-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100433300B1 (en) | Feed product | |
| CN102212495B (en) | Lactobacillus acidophilus and application thereof | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN115094012B (en) | Preparation method and application of bacillus coagulans BC-HYC strain microbial inoculum | |
| CN115287224B (en) | Yak-source lactobacillus reuteri for improving intestinal microbial development of indigenous animals and application of yak-source lactobacillus reuteri | |
| CN109321505A (en) | A kind of complex microorganism preparations adjusting aquatic livestock enteron aisle | |
| CN100482104C (en) | Process for preparing lactic acid bacteria oral liquor | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN108949613B (en) | Antibiotic-assisting probiotic preparation and preparation method thereof | |
| CN112471353A (en) | Long-acting symbiotic composite liquid microecological preparation for poultry feeding and preparation method thereof | |
| CN116200305A (en) | Enterococcus durans strain with anti-inflammatory property, culture method and application | |
| CN109486732B (en) | Bifidobacterium longum and application thereof | |
| CN113598285A (en) | Traditional Chinese medicine fermented feed for improving intestinal immunity of aquaculture animals and preparation method thereof | |
| CN117467581A (en) | Pediococcus acidilactici King73 capable of improving canine immunity and application thereof | |
| CN107686826A (en) | The preparation method and pig feed of a kind of bacillus coagulans and its fermentation process, bacillus coagulans preparation | |
| CN108795829B (en) | Bacillus subtilis and application thereof in microbial inoculum and pork pig feed | |
| CN116790402A (en) | Bacteroides simplex strain with anti-inflammatory property, culture method and application | |
| CN114657082B (en) | Lactococcus lactis and application thereof | |
| CN106387314A (en) | Applications of Bacteroides fragilis in animal breeding | |
| CN1162089C (en) | Microecological regulator for animal and fowl | |
| CN1796540A (en) | Bifidobacterium with anti-intestinal pathogenic bacteria and antioxidant properties and application thereof | |
| CN111849827B (en) | Dog-derived lactic acid bacteria capable of producing vitamin B12 and application | |
| JPH05292947A (en) | Lactobacillus-acidophilus pn-ri-2-4, lactic acid bacterial formulation using the same and its production | |
| CN106666150A (en) | Nonreactive health-care agent capable of improving production performance of breeding pigs and preparation method of nonreactive health-care agent | |
| CN1857326A (en) | Lactobacillus probiotics preparation and its preparing method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A probiotic preparation for auxiliary antibiotics and its preparation method Effective date of registration: 20230517 Granted publication date: 20210323 Pledgee: Hubei Science and Technology Financing Guarantee Co.,Ltd. Pledgor: HUBEI HUADA REAL TECHNOLOGY Co.,Ltd. Registration number: Y2023980040908 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210323 Pledgee: Hubei Science and Technology Financing Guarantee Co.,Ltd. Pledgor: HUBEI HUADA REAL TECHNOLOGY Co.,Ltd. Registration number: Y2023980040908 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A probiotic preparation for auxiliary antibiotics and its preparation method Granted publication date: 20210323 Pledgee: Hubei Science and Technology Financing Guarantee Co.,Ltd. Pledgor: HUBEI HUADA REAL TECHNOLOGY Co.,Ltd. Registration number: Y2024980021933 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |